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Isolated bone marrow mastocytosis: an 
underestimated subvariant of indolent 
systemic mastocytosis 
Systemic mastocytosis (SM) is a heterogeneous disor-
der characterized by the proliferation and accumulation
of atypical mast cells (MC) in tissues, principally in the
bone marrow (BM) and skin. The diagnosis of systemic
mastocytosis requires the presence of multifocal dense
mast cell infiltrates in one or multiple extra-cutaneous
organs, mostly bone marrow (major criterion), plus at
least one of the following minor criteria: i) abnormal mor-
phology of extra-cutaneous mast cells (spindle-shaped
cells); ii) increased serum tryptase level (>20 ng/ml); iii)
abnormal expression of CD2 and/or CD25 on bone mar-
row mast cells; iv) detection of a KIT mutation at codon
816 in extra-cutaneous organs.1 Diagnosis of systemic
mastocytosis can also be made in the presence of at least
3 minor criteria. According to the World Health
Organization (WHO) systemic mastocytosis was grouped
into 4 major clinical variants: 1) indolent systemic masto-
cytosis; 2) systemic mastocytosis with an associated clon-
al, hematologic, non-mast cell lineage disease; 3) aggres-
sive systemic mastocytosis; and 4) mast cell leukemia
based on distinct clinico-pathological features. On the
basis of the presence of two or more B-findings, indolent
systemic mastocytosis can be subclassified as smoldering
systemic mastocytosis (SSM).2
A lack of skin lesions has been described in cases of
aggressive systemic mastocytosis and mast cell leukemia,
but also in bone marrow mastocytosis (BMM), a subvari-
ant of indolent systemic mastocytosis recognized by the
2008 WHO classification.2 Diagnosis of systemic masto-
cytosis in the absence of typical skin involvement pres-
ents a challenge for clinicians. It should be considered in
the differential diagnosis for a number of clinical condi-
tions, such as unexplained anaphylaxis, osteoporosis of
unknown etiology, etc. Moreover, indolent systemic mas-
tocytosis without skin lesions has been frequently report-
ed in patients with systemic allergic reaction to
hymenoptera venom and raised basal tryptase.3
We report the characteristics of 99 consecutive indolent
systemic mastocytosis patients, diagnosed or revised
according to the 2008 WHO classification2 from January
2005 to December 2009 at the Multidisciplinary
Outpatient Clinic for Mastocytosis in Verona, Italy.
These patients were among 145 patients referred from a
regional network of Allergists and Dermatologists, fol-
lowing the appearance of classic skin lesions, or in the
case of unexplained/recurrent anaphylaxis or severe aller-
gic reactions to hymenoptera sting with persistent raised
tryptase. They had complete blood cell count, routine
biochemistry, abdominal ultrasonography, bone densito-
metry evaluation with Dual-energy X-ray
Absorptiometry and, in selected cases, skeletal X-ray. All
patients had a bone marrow evaluation with bone mar-
row histology/cytology, flow cytometric analysis, and
detection of KIT mutation, performed as previously
described.4 Anaphylaxis was defined according to the
European Academy of Allergology and Clinical
Immunology and World Allergy Organization criteria
(2003).5 Approval for this study was obtained from the
Azienda Ospedaliera Universitaria Integrata of Verona’s
institutional review board.
Sixty-one patients showed classic skin lesions: a diag-
nosis of indolent systemic mastocytosis (ISMs+) was
made in 51 of 61 subjects, 2 patients were diagnosed
with smoldering systemic mastocytosis and 8 were clas-
sified as cutaneous mastocytosis. Isolated bone marrow
mastocytosis was diagnosed in 46 of 84 patients (54.7%)
referred for unexplained/recurrent anaphylaxis or severe
allergic reactions to hymenoptera sting without skin
lesions. Another 13 patients fulfilled less than 3 minor
criteria but displayed mast cell clonality markers and
were considered as having monoclonal mast cell activa-
tion syndrome.6,7 The major diagnostic criterion and at
least one minor criterion were fulfilled on bone marrow
evaluation in 68.0% of indolent systemic mastocytosis
with skin involvement and in 39.5% of bone marrow
mastocytosis patients (Table 1). 
Clinical and biological characteristics of 46 bone mar-
row mastocytosis, 51 indolent systemic mastocytosis
with skin involvement and 2 smoldering systemic masto-
cytosis patients are summarized in Table 2. There were
51 males and 48 females (median age 47 years, range 19-
80). After a median of 26 months from diagnosis (range
6-104) all patients were alive with stable disease and con-
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Table 1. Bone marrow evaluation of 99 indolent systemic mastocytosis patients.
BMM ISMs+ P SSM
(BMM vs. ISMs+)
Number of patients 46 51 2
BM histology*
- BM cellularity, median % (range) 40 (20-70) 40 (10-80) NS§ 70, 80
- Multifocal, dense MC aggregates n. (%) 17/43 (39.5) 34/50 (68.0) 0.004§ 2/2 (100)
- Isolated MC or small aggregates of MC (%)** 26/43 (60.5) 16/50 (32.0) 0
BM cytology°
Atypical MC type I >25% of BM MC n. (%) 32 (69.6) 46 (90.2) 0.011§ 2/2 (100)
Flow cytometry on BM
BM MCs median % of MNC (range) 0.11 (0.005-0.7) 0.12 (0.01-2.3) 0.031+ 0.3, 2.3
BM MCs co-expressing CD25, % of MC (range) 92 (13-100) 95 (54-100) NS+ 96, 97
D816V mutation of KIT, n. (%) 35/40 (87.5) 41/45 (91.1) NS§ 2/2 (100)
BMM: bone marrow mastocytosis; ISMs+: indolent systemic mastocytosis with skin involvement; SSM: smoldering systemic mastocytosis; BM: bone marrow; MC: mast cells; NS:
not significant; §: χ2 test; +: t-test. *BM biopsy was not performed in 4 to 99 cases, because of patient's refusal or vago-vagale reaction after BM aspirate. In these 4 cases diagnosis
of SM was established on the basis of three minor criteria. **the diagnosis of SM was established on the basis of three minor criteria. °atypical MC type II were not documented.  
stant serum tryptase levels; 2 bone marrow mastocytosis
patients presented a severe disability following cerebral
hypoxia due to a severe reaction to hymenoptera venom.
Bone marrow mastocytosis patients were predominantly
males and had a lower bone marrow mast cell burden, as
evaluated by flow-cytometry, serum tryptase level and
incidence of mediator-related symptoms other than ana-
phylaxis, than indolent systemic mastocytosis cases with
skin involvement. Lower hemoglobin level documented
in indolent systemic mastocytosis patients with skin
involvement was related to a higher percentage of female
patients in this group. 
Pardanani and Tefferi have recently demonstrated that
bone marrow mastocytosis is not as rare as previously
believed.8 Indeed 39 out of 159 (23%) indolent systemic
mastocytosis patients referred to their institution during
a period of about 20 years had bone marrow mastocyto-
sis and 86% of them had history of anaphylactoid reac-
tions; they were prevalently men, had lower tryptase lev-
els, and a lower incidence of B-findings and constitution-
al symptoms than other types of indolent systemic mas-
tocytosis. However, in a proposal to revise the systemic
mastocytosis classification, they suggest that this subvari-
ant can be removed due to its limited relevance.9
In our opinion, the incidence of indolent systemic mas-
tocytosis limited to bone marrow has been frequently
underestimated. Although it is a rare condition, close col-
laboration between different specialists could improve
detection of this disease. In our experience a high number
of bone marrow mastocytosis patients was detected in a
relatively short period of time due to the creation of a
multidisciplinary regional network and the availability of
very sensitive diagnostic procedures. Because bone mar-
row mastocytosis could underlie unexplained anaphylax-
is or severe allergic reactions even with normal tryptase
levels,10 it could be hypothesized that the actual frequen-
cy of bone marrow mastocytosis is still underestimated.
Evaluation of clinical characteristics of the allergic reac-
tions, i.e. the presence of syncope in the absence of
urticaria/angioedema, could be helpful to identify those
subjects who are likely to have bone marrow mastocyto-
sis before a bone marrow study, as recently proposed by
Alvarez-Twose et al.11
We believe that early recognition of bone marrow mas-
tocytosis is essential to reduce potential life-threatening
events or severe skeletal complications. Moreover,
patients with systemic reactions to hymenoptera venom
should be considered for life-long venom immunothera-
py.4 Our data and the series presented by Alvarez-Twose
et al.11 suggest that indolent systemic mastocytosis limit-
ed to the bone marrow could represent a distinct disease
subtype with a strong association with anaphylactic reac-
tions and little or no probability of a progressive course.
Nevertheless, collaborative longitudinal studies are need-
ed to better evaluate these conditions and to establish
common definitions.
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Table 2. Clinical and laboratory characteristics of 99 indolent systemic mastocytosis patients.
BMM ISMs+ P SSM
(BMM vs. ISMs+)
Number of patients 46 51 2
M/F 31/15 19/32 0.003§ 1/1
Median age at diagnosis, yrs (range) 50 (19-75) 43 (22-80) NS+ 46, 74
Median time from first symptoms or signs, months (range) 43 (3-441) 112 (4-492) NS+ 9, 300
Median serum tryptase level, ng/mL (range) 24.0 (10.6-108) 40.0 (7.7-500) 0.002+ 250, 760
Hemoglobin, median gr/dl (range) 15.0 (11.6-16.7) 13.8 (11.3-16.9) 0.010+ 12.9, 13.5
White cell count, median x109/L (range) 6.5 (3.0-12.5) 6.0 (3.4-14.0) NS+ 7.3, 9.3
Platelet count,  median x109/L (range) 250 (137-404) 298 (132-421) NS+ 167, 421
Hepatosplenomegaly, n. (%) 0 (0) 2 (3.8) NS§ 2 (100)
Lymphadenopathy,  n. (%) 0 (0) 1 (1.9) NS§ 1 (50)
Constitutional symptoms, n. (%) 0 (0) 0 (0) NS§ 1 (50)
Mediator-related symptoms,*  n. (%) 8 (17.2) 25 (49.0) <0.001§ 2 (100)
Anaphylaxis, n° (%) 44** (95.6) 14 (27.4) <0.0001§ 0
- after hymenoptera sting 42 (91.3) 11 (21.6)
- after diptera sting 0 (0) 1 (2.0)
- after drug or food 1 (2.2) 2 (3.9)
- unexplained 1 (2.2) 0 (0)
BMM: bone marrow mastocytosis; ISMs+: indolent systemic mastocytosis with skin involvement; SSM: smoldering systemic mastocytosis; BM: bone marrow; MC: mast cells;
NS: not significant; §: χ2 test; +: t-test. * excluding anaphylactic episodes; ** 2 patients had no severe systemic reaction after hymenoptera sting.
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